Table 2.
Prevalence of thyroid dysfunction, stratified by amiodarone and levothyroxine use
| Thyroid category | Entire population n=1365 |
Amiodarone users n= 151 |
Levothyroxine users n=173 |
Excluding amiodarone & levothyroxine users n=1070 |
|---|---|---|---|---|
| Euthyroid | 1006 (73.7) | 64 (42) | 79 (45.7) | 870 (81.3) |
| Overt hypothyroid | 4 (0.3) | 2 (1.3) | 3 (1.7) | 1 (0.1) |
| Subclinical hypothyroid | ||||
| Overall | 74 (5.4) | 21 (13.9) | 28 (16.2) | 35 (3.3) |
| TSH 4.51 to 6.99 mIU/L | 48 (3.5) | 12 (7.9) | 13 (7.5) | 28 (2.6) |
| TSH 7.00 to 19.99 mIU/L | 26 (1.9) | 9 (6.0) | 15 (8.7) | 7 (0.7) |
| Subclinical hyperthyroid | 69 (5.1) | 4 (2.6) | 19 (11.0) | 47 (4.4) |
| Overt hyperthyroid | 15 (1.1) | 5 (3.3) | 8 (4.6) | 4 (0.4) |
| Low T3 syndrome | 197 (14.4) | 55 (36.4) | 36(20.8) | 113 (10.6) |
| Anti-TPO antibody positive | 123 (9.0) | 11 (7.3) | 41 (23.7) | 75 (7.0) |
Data presented as n (%).
TSH, thyroid stimulating hormone; T3, triiodothyronine; TPO, thyroid peroxidase